Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 5 of this Exclusive Interview, Dr. Vinik explains the caution on the part of doctors to use the latest SGLT-2 medications despite apparent benefits.
Aaron Vinik, MD, PhD, FCP, MACP, FACE is the Director of Research and the Neuroendocrine Unit
Murray Waitzer Endowed Chair for Diabetes Research at Eastern Virginia Medical School. He is a national leader in basic and clinical neuropathy and pioneered the use of immunotherapy for autoimmune diabetic neuropathy. His research on islet regeneration and the discovery of a gene, INGAP (islet neogenesis associated protein), garnered international recognition as a potential cure for diabetes. The gene is responsible, either alone or in combination with other factors, for stimulating immature cells in the diabetic pancreas to produce insulin.
If you prefer to view the entire video, click here.
To view other segments in this video: